Balasubramanian Priya, Delfavero Jordan, Nyul-Toth Adam, Tarantini Amber, Gulej Rafal, Tarantini Stefano
Vascular Cognitive Impairment and Neurodegeneration Program, Department of Biochemistry and Molecular Biology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States.
International Training Program in Geroscience, Institute of Biophysics, Biological Research Centre, Eötvös Loránd Research Network (ELKH), Szeged, Hungary.
Front Aging. 2021 Sep 23;2:678543. doi: 10.3389/fragi.2021.678543. eCollection 2021.
Growing life expectancy will contribute to the on-going shift towards a world population increasingly comprised of elderly individuals. This demographic shift is associated with a rising prevalence of age-related diseases, among all age-related pathologies it has become crucial to understand the age-associated cognitive changes that remain a major risk factor for the development of vascular cognitive impairment and dementia (VCID). Furthermore, age-related Alzheimer's disease and other neurogenerative diseases with vascular etiology are the most prominent contributing factors for the loss of cognitive function observed in aging. Hyperbaric Oxygen Therapy (HBOT) achieves physiologic effects by increasing oxygen tension (PO2), raising oxygen tissue levels, decreasing intracranial pressure and relieving cerebral edema. Many of the beneficial effects of HBOT exert their protective effects at the level of the microcirculation. Furthermore, the microcirculation's exquisite pervasive presence across every tissue in the body, renders it uniquely able to influence the local environment of most tissues and organs, including the brain. As such, treatments aimed at restoring aging-induced functional and structural alterations of the cerebral microcirculation may potentially contribute to the amelioration of a range of age-related pathologies including vascular cognitive impairment, Alzheimer's disease, and vascular dementias. Despite the presented evidence, the efficacy and safety of HBOT for the treatment of age-related vascular cognitive impairment and dementia remains understudied. The present review aims to examine the existing evidence indicative of a potential therapeutic role for HBOT-induced hyperoxia against age-related cerebromicrovascular pathologies contributing to cognitive impairment, dementia and decreased healthspan in the elderly.
预期寿命的增长将促使世界人口持续向老龄化转变。这种人口结构的转变与年龄相关疾病的患病率上升有关,在所有与年龄相关的病理状况中,了解与年龄相关的认知变化至关重要,因为这些变化仍然是血管性认知障碍和痴呆(VCID)发生的主要危险因素。此外,与年龄相关的阿尔茨海默病和其他具有血管病因的神经退行性疾病是衰老过程中观察到的认知功能丧失的最主要促成因素。高压氧疗法(HBOT)通过增加氧分压(PO2)、提高组织氧水平、降低颅内压和减轻脑水肿来实现生理效应。HBOT的许多有益作用在微循环水平发挥其保护作用。此外,微循环在身体每个组织中广泛存在,使其能够独特地影响包括大脑在内的大多数组织和器官的局部环境。因此,旨在恢复衰老引起的脑微循环功能和结构改变的治疗方法可能有助于改善一系列与年龄相关的病理状况,包括血管性认知障碍、阿尔茨海默病和血管性痴呆。尽管有上述证据,但HBOT治疗与年龄相关的血管性认知障碍和痴呆的疗效和安全性仍未得到充分研究。本综述旨在研究现有证据,表明HBOT诱导的高氧对导致老年人认知障碍、痴呆和健康寿命缩短的与年龄相关的脑微血管病理具有潜在治疗作用。